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Following the discovery of the human immunodeficiency virus (HIV), our knowledge of HIV infection and management has increased 
rapidly, but implementation of interventions has been slow in resource-limited settings. In particular, interventions such as antiretroviral 
treatment (ART) and prevention of mother-to-child transmission were hindered owing to lack of access to antiretroviral drugs. This resulted 
in ongoing HIV transmission, morbidity and mortality associated with opportunistic infections. Notwithstanding the current progress in 
HIV prevention and treatment, challenges remain in preventing new infections in adolescents and supporting and treating HIV-infected 
adolescents. Barriers to successful treatment of infection in adolescents include denial of diagnosis, poor understanding or perception 
of future benefits of treatment and current-orientated thinking that may contribute to non-adherence to ART. Side-effects that lead to 
stigmatisation, such as lipoatrophy (stavudine, zidovudine), diarrhoea and flatulence (lopinavir/ritonavir) and gynaecomastia (efavirenz), may 
be intolerable and prevent adherence to treatment. This article highlights common treatment issues in HIV adolescent care and provides 
guidance on their management in the South African setting.
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Adolescents as a group undergo rapid biological and 
social role changes.[1] The World Health Organization 
(WHO) defines adolescents as individuals in the 
age group 10 - 24 years.[1] The South African (SA) 
Department of Health’s definition of adolescence is 
in line with those of the United Nations (UN) and the WHO – an 
adolescent is described as a young person aged between 10 and 
19 years.[2] In 2013, of the estimated 35 million people living with 
HIV, there were  approximately 210 000 new HIV infections among 
children in sub-Saharan Africa.[3] In SA, women aged 15 - 24 years 
are the group with the highest rate of new HIV infections and should 
therefore be considered to be most at risk.[2] Among this age group, 
heterosexual transmission of HIV infection is the predominant risk 
factor.[2]
With the implementation of the SA HIV antiretroviral drug 
treatment guidelines in 2004, there was increased access to anti-
retroviral treatment (ART) for adults and children.[4] The number 
of children with HIV infection requiring long-term treatment is 
increasing in SA owing to improved survival of those initiated on 
ART, an increase in the number of long-term HIV disease non-
progressors and an increase in behavioural HIV transmission 
among adolescents. While addressing the needs of HIV-infected 
adolescents is a national priority, the optimal treatment regimen 
for children and adolescents remains a challenge in SA and 
internationally. There is a lack of information with regard to 
pharmacokinetics and safety and efficacy data in children and 
adolescents. While the current guidelines are helpful and based on 
expert opinion, evidence-based management of adolescent HIV is 
urgently required.[5]
Adolescence and HIV infection
Adolescence is a unique period of rapid physical, biological, 
intellectual, behavioural and emotional growth.[6] This heterogeneous 
group of pubertal children and young adults are more vulnerable and 
at an increased risk of HIV acquisition.[7] Furthermore, adolescents 
are less likely to present for testing or be tested for HIV infection.[8] 
Young women are often diagnosed with HIV after the diagnosis of an 
unplanned pregnancy, leading to the dual impact of a new diagnosis 
and an unplanned pregnancy.
Biological factors such as the presence of a sexually transmitted 
infection (STI), exposure to partners with acute HIV infection, 
and sharing partners within sexual networks may increase the 
likelihood of HIV exposure to a recently infected partner. In 
young women, the immature cervix is lined with columnar 
epithelium instead of squamous epithelium; this may increase 
the susceptibility to HIV infection.[9] Moreover, larger thymic 
volume and activity in adolescents may slow natural progression 
to acquired immune-deficiency syndrome (AIDS) compared with 
older adults.[10]
Sexual practices among adolescents play an important role in 
HIV transmission. They do not consider oral or anal sex as ‘real sex’. 
Oral sex is viewed as less risky and often this is not explored in the 
sexual history.[11] Physicians usually communicate ineffectively and 
are unclear when obtaining a sexual history; hence, risky behaviours 
are often missed. Sexual reproductive healthcare is central to 
medical care of adolescents and should include screening for STIs, 
risk-reduction counselling and contraception counselling. Human 
papillomavirus vaccination and screening are important elements 
of this care.[12]
HIV counselling, testing and 
disclosure 
After testing for HIV infection adolescents are less likely to link 
to services for prevention (barrier and hormonal contraception 
access, circumcision) and treatment interventions. The following 
groups of adolescents (key populations) are considered to be most 
at risk for HIV and STIs: adolescent males who have sex with men, 
adolescents who are sexually exploited or engage in sex work, 
adolescents who abuse substances, transgender adolescents (male 
and female), adolescents affected by AIDS (orphans, children of 
chronically ill caregivers), and adolescent clients of sex workers 
and the partners of these clients.[2] It should be noted that the 
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Children’s Act 38 of 2005 enables a child of ≥12 years with 
sufficient emotional and mental maturity to comprehend the risks 
and benefits of treatment to consent to HIV testing and treatment 
without parental consent.[13]
HIV testing and counselling (HTC), with linkages to prevention, 
treatment and care, should be offered to all adolescents as a priority, 
especially those in the designated high-risk groups. Counselling, 
with an emphasis on the potential benefits and risks of HIV 
disclosure, should be offered before and after testing. This group 
should be empowered and supported to disclose their HIV status. 
Underutilisation of HTC services results in late diagnosis and 
complications associated with HIV infection.[12]
The support during disclosure may include healthcare providers, 
parents, peers and the community. Privacy, confidentiality and 
support to cope with negative reactions such as discrimination 
and alienation from family, friends and community are essential to 
successful HIV testing and disclosure, access to treatment, linkage 
and retention in care. Disclosure of HIV status is a continuous 
process that occurs throughout adolescence and ranges from 
informing young people of their HIV status (either at diagnosis 
or later, depending on their age) to adolescents independently 
sharing their HIV status with others when they are ready to do 
so. Adolescents need support from healthcare providers, peers 
and the community to disclose safely and confidentially, and to 
be able to cope with any negative reactions from family, friends 
and their community. Key adolescent populations are particularly 
sensitive to confidentiality issues as they are often at risk of legal 
consequences and abuse linked to their high-risk practices and 
lifestyles.
Adolescent HIV treatment in SA
Current evidence suggests that survival of HIV-infected adolescents 
is associated with effective ART. The current SA ART guideline 
(2015) recommends ART for all children 10 - 15 years of age with 
WHO clinical stage 3 or 4 disease or a CD4 count ≤500 cells/μL.[2] 
Those with a CD4 count of ≤200 cells/μL, WHO stage 4 disease, 
multidrug- or extreme drug-resistant tuberculosis (MDR/XDR-
TB) should initiate ART within 7 days of establishing eligibility 
to commence treatment. Pregnant adolescent women should be 
commenced on ART, irrespective of the CD4 count or WHO clinical 
stage. 
The guidelines make a distinction in the recommended nucleoside 
reverse-transcriptase inhibitor (NRTI) choice for treatment of 
adolescents based on age and weight. Adolescents <40 kg or 
<15 years should be commenced on abacavir and lamivudine or 
emtricitabine together with efavirenz. Those with an undetectable 
viral load (VL) (<50 copies/mL) and no adverse events may 
remain on this regimen until eligible for transition to the fixed-
dose combination pill (tenofovir, emtricitabine and efavirenz) at 
15 years and if their weight is >40  kg. Prior to this transition, a 
creatinine clearance (CrCl) and  urine dipstick examination should 
be performed to exclude renal disease. If the CrCl is <80 mL/min 
or >1+ proteinuria is observed on urine dipstick examination the 
patient should be referred for expert advice before transition to the 
fixed-dose combination pill.
Adolescents who fail first-line ART, defined by two consecutive VL 
measurements >1 000 copies/mL more than 1 month apart in spite 
of good adherence, should be changed to a second-line regimen of 
zidovudine and lamivudine together with lopinavir/ritonavir. Before 
changing this regimen, the hepatitis B status should be checked. If 
the patient is hepatitis B surface antibody positive, tenofovir should 
be added.
Adolescents who fail second-line therapy should be referred to a 
specialist for planning and motivation of third-line ART. The choice 
of regimen is based on HIV genotype resistance testing, previous drug 
exposure, potential mutations and expert opinion.
Case vignette
A 13-year-old boy was commenced on ART (stavudine, lamivudine 
and efavirenz) in June 2009. His baseline CD4 count was 168 cells/µL 
and VL 86 342 copies/mL. His VL was undetectable at 6 months and 
1 year after commencing ART. The first VL suppression was only 
recorded in August 2010. Throughout this time he was counselled on 
the importance of using his medication as prescribed.
In July 2011, the treatment regimen was changed to tenofovir, 
lamivudine and efavirenz. The VL was detectable in February 2012 
(10  983 copies/mL), although he always reported taking his medi-
cation. The regimen was then changed to second-line treatment of 
tenofovir, lamivudine and lopinavir/ritonavir (Aluvia). In July 2012, 
despite the change in regimen, his VL remained detectable (12  589 
copies/mL). Genotype resistance tests indicated resistance to non-NRTIs 
only. The patient remained on second-line treatment.
In early 2013, the VL was 20  000 copies/mL. At that stage his 
grandmother reported that the HIV diagnosis was disclosed to him 
and he was non-adherent with his medication. He received extensive 
counselling with regard to risk reduction and adherence to ART.
Learning points: There are several barriers that challenge success-
ful treatment in HIV-infected adolescents. Denial of diagnosis and 
poor understanding of the need for treatment are common, especially 
among those recently infected.[14] An adolescent’s perception of 
the future benefits of treatment is limited by concrete and current-
orientated thinking. Side-effects that lead to stigmatisation, such 
as lipoatrophy (stavudine, zidovudine), diarrhoea and flatulence 
(lopinavir/ritonavir) and gynaecomastia (efavirenz), may be intole-
rable.[12] Failure or fear of disclosure may result in mistrust of 
parents and medical treatment providers. Rebellion against parents 
and other authority could lead to poor adherence after long 
periods of compliance.[12] Misinformation, lack of family support 
and stigmatisation from peers may further influence adherence. 
Mental health issues, such as depression, low self-esteem and 
hopelessness, and substance abuse could further influence medi-
cation compliance.[12]
Different strategies to improve adherence include pill boxes, 
reminder systems (cellular telephone alarms, short messaging 
services (SMS)) to maintain daily schedules, peer-to-peer adherence 
messages and counselling together with healthcare provider and 
parent support.[12] Low pill burden and once-daily treatment regimens 
with minimal side-effects also impact on long-term compliance.[7] 
Attention to monitoring adherence and providing ongoing support 
are key to effective ART.
Conclusion
There remain barriers to the development and sustainability of 
comprehensive multidisciplinary care for adolescents, such as 
fragmented, vertical healthcare systems, transportation, distance, 
timing and access to services. Ideally, there should be specialised 
services at accessible sites such as mobile or outreach clinics together 
with consultation with HIV and other experts.[15] Transition to adult 
services may pose a challenge to the young adult and consideration 
should be given to a stepwise transition plan to a multidisciplinary 
team, e.g. gynaecology services, general primary care providers and 
adult HIV specialists. Adolescents require access to appropriate, 
comprehensive healthcare services to benefit from effective HIV 
prevention and treatment strategies.
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